Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gottlieb Showing Capitol Hill Skills With Funding Success

Executive Summary

US FDA gains $94m in new funding for international mail facilities, a priority for the commissioner, along with an increase in non-user fee dollars for agency operations.
Advertisement

Related Content

US FDA's Sunscreen Progress Gets Dim Review From Congressional Appropriators
Patient Experience Data: Industry Seeks US FDA Clarity On Submission Pathway And Labeling
US FDA's Cancer Review Staff Should All Move To Oncology Center of Excellence, Advocates Say
Gottlieb's Priority For Proposed Opioid Money Is Mail Facilities
Trump's Budget Surprise: FDA Gains 13% Increase
US FDA's China Staff Increase Takes Hold As Gottlieb Boosts Border Security
US FDA Still Waiting For Cures Money, Woodcock Says
US FDA Getting More Money Up Front Under Cures Bill Revisions
FDA Secure Supply Chain Pilot Draws Small Group, But Could Serve Globalization Goals
FDA’s Hand-Held Rx Counterfeit Detector Could Roll Out To Developing Nations

Topics

Advertisement
UsernamePublicRestriction

Register

PS122773

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel